Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.
about
Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy.Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease.Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.Atypical antipsychotic usage among Asian Americans and Pacific Islanders.Time trends in method-specific suicide rates in Japan, 1990-2011.Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009.Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Safety and tolerability of antipsychotic polypharmacy.Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia.Antipsychotics prescribing patterns of patients with schizophrenia admitted to korean general hospital psychiatric unit: 2001 to 2008.The prevalence and risk factors of stroke in patients with chronic schizophrenia.International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practicePredictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in MalaysiaPharmacotherapy for schizophrenic inpatients in East Asia--changes and challenges.Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria.Antipsychotic polypharmacy in schizophrenia: benefits and risks.Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups.Gender differences and psychotropic polypharmacy in psychiatric patients in Brazil: a cross-sectional analysis of the PESSOAS Project.Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia.Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy.Prescribing patterns of low doses of antipsychotic medications in older Asian patients with schizophrenia, 2001-2009.Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009.[Prevalence and characteristics of neuroleptic association in a patient cohort with psychotic disorders].Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines.Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy.Are antipsychotic prescribing patterns different in older and younger adults?: a survey of 1357 psychiatric inpatients in Toronto.Addition of antipsychotics to medication regimens during schizophrenic inpatient care.Rationale for emphasis on management over treatment of schizophrenia in clinical practice.
P2860
Q33455799-6E2B45EE-D561-4EB2-8694-B335ED042D31Q33560808-CDCF121A-B938-4D4A-BFFF-3730EE4D2501Q33813264-FE5524E5-93DE-4A18-875F-5879FEEBB4D2Q33972014-444ED044-2146-49D1-B87B-156908E11A1EQ34241856-F0ED71AE-50F5-4673-9807-55F2F4D87372Q34446472-1EA13A95-FD28-440B-9E44-DC055B014F42Q34770565-31E0E473-A66F-421D-AFA9-6727120D9988Q35608522-9E0DD3B9-439E-46C7-918F-75C83B40B303Q36057820-46E786E4-FE74-45D2-9F45-4A78F9709949Q36062421-BEB30D0E-F6AE-483D-8CB2-59C2E90718D8Q36556487-A62FB371-4870-4C99-9087-35397DF660DCQ36599207-E89A0649-6A86-4A40-8B64-8D9D92D9AB37Q36908408-A7A74535-244F-444E-A18E-F0E896EC5A06Q36944064-7657F09D-7E9B-4232-AED4-0375C27BE48AQ37029622-E25C47E3-2E9B-4CDC-B221-5ED16294119EQ37042072-D16546B4-AAA7-430C-B598-A8ADF4FBAC85Q37156296-0C09A7D9-05F8-4AA1-823F-B8859505CDC8Q37281587-A7098287-655F-430E-BBB3-1F24F5975E05Q37294192-19B202CC-30A9-403C-B7F0-C81EE44C8E8AQ37326610-D6CBB10F-4CD5-4D1B-A903-CF7D7DDA3858Q37582708-FA005FA1-8F1B-48B7-AC18-2C815E48C3EEQ37863093-8C123307-3FA0-4A24-B2DC-A29823AEC68EQ38700601-17244A47-E237-4E01-9A3E-0C443CABEF4FQ38766834-F026A380-024D-4E7F-AD29-E0B4E68F49FFQ38855605-C9FA9C5D-757E-4AAD-8183-2299594D1D8FQ41483833-C9FD5A1D-2A11-4E2C-A1BF-058C84C9B2E9Q41682303-F23E35B2-C197-4421-AD3A-60FC1850BA29Q42707831-B5EBE3D3-8485-4AF2-BAAF-B489C62F0F24Q42835527-8150F1AB-15EF-4F69-AF32-FDAB6FC45AD0Q42860052-2DD8EB77-D353-4BAA-87F5-5D96D2A00255Q44490282-CF369F68-F27C-4631-B5F9-506A981B95C4Q44897335-DCA27061-3801-421C-872A-CC258F1ADC18Q44940734-89242C81-CF4A-4433-850A-ECDF9DD1F6B4Q45143157-6E1622AC-0AD4-4C71-9315-B0767E0CAC14Q46721830-B5CD5AE8-EC2C-4CAB-82C0-BC7AA38DB309Q50804521-F5AC1C56-4C23-46E5-817C-9A6D7DD3E942Q51852408-EF029C01-D6B9-4F7D-8058-E88438403C7DQ51893657-F3B87DD1-8717-47B9-9249-5B408C5F7178Q51905431-461870BB-D355-4AA4-BBDD-A1A33655542A
P2860
Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antipsychotic polypharmacy in ...... omparative study in East Asia.
@ast
Antipsychotic polypharmacy in ...... omparative study in East Asia.
@en
type
label
Antipsychotic polypharmacy in ...... omparative study in East Asia.
@ast
Antipsychotic polypharmacy in ...... omparative study in East Asia.
@en
prefLabel
Antipsychotic polypharmacy in ...... omparative study in East Asia.
@ast
Antipsychotic polypharmacy in ...... omparative study in East Asia.
@en
P2093
P2860
P1476
Antipsychotic polypharmacy in ...... omparative study in East Asia.
@en
P2093
Chay H Tan
Eun K Chung
Gabor S Ungvari
Hin-Yeung Tsang
Mian-Yoon Chong
Naotaka Shinfuku
Senta Fujii
Shu-Yu Yang
P2860
P304
P356
10.1111/J.1365-2125.2004.02102.X
P407
P577
2004-08-01T00:00:00Z